Puma Biotechnology Inc - Common Stock — Balance Sheet (NASDAQ:PBYI) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 244.22 M226.59 M222.06 M230.53 M213.33 M216.3 M Total liabilities 250.17 M229.03 M200.45 M177.09 M121.21 M85.96 M Total equity -5.95 M-2.45 M21.61 M53.44 M92.13 M130.34 M Total liabilities & shareholders' equities 244.22 M226.59 M222.06 M230.53 M213.33 M216.3 M Total debt 84.03 M97.09 M98.31 M65.66 M21.72 M22.52 M Net debt 84.03 M27.24 M51.76 M16.74 M-65.12 M-91.63 M

Puma Biotechnology Inc - Common Stock

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

News

PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript

Puma Biotechnology, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-05-08

Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?

PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View

Puma Biotechnology, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-02-27

Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates